MDXG
Mimedx Group Inc
NASDAQ · Biotechnology
$5.15
+0.12 (+2.39%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 346.66M | 313.72M | 209.33M | 190.63M | 232.96M |
| Net Income | 42.15M | 34.33M | 28.77M | 27.70M | 27.53M |
| EPS | — | — | — | — | — |
| Profit Margin | 12.2% | 11.6% | 13.8% | 14.5% | 11.8% |
| Rev Growth | +10.5% | +10.5% | +3.6% | +8.9% | +19.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 33.88M | 33.88M | 186.36M | 233.39M | 246.36M |
| Total Equity | 347.48M | 347.48M | 331.06M | 355.89M | 342.73M |
| D/E Ratio | 0.10 | 0.10 | 0.56 | 0.66 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 59.30M | 50.98M | 34.33M | 34.17M | 44.70M |
| Free Cash Flow | — | — | 35.16M | 29.04M | 38.48M |